VALERIA BERMUDEZ: Open Payments
NPI 1992158257 · BROWNSVILLE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$885 in 47 payments from 14 companies in 2025. Trend: 2023 $1,548 · 2024 $996 · 2025 $885
Food & beverage: $885
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 15 | $308 |
| Novo Nordisk Inc | 14 | $164 |
| Mayne Pharma Commercial LLC | 1 | $125 |
| AstraZeneca Pharmaceuticals LP | 4 | $62 |
| Sumitomo Pharma America, Inc. | 2 | $37 |
| GlaxoSmithKline, LLC. | 2 | $30 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $29 |
| Insulet Corporation | 1 | $22 |
| Novartis Pharmaceuticals Corporation | 1 | $21 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $20 |
Products named: ZEPBOUND, MOUNJARO, ANNOVERA, Ozempic, AIRSUPRA, Wegovy, GEMTESA, SHINGRIX.
Industry payments across TX — which companies pay providers there.
